Candesartan cilexetil: A new, long-acting, effective angiotensin II type 1 receptor blocker

Journal of Human Hypertension

Volumn 11, Issue SUPPL. 2, 1997, Pages

  Sever, P ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Angiotensin II AT1 receptor blocker; Candesartan cilexetil; Hypertension; Review

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO; PRODRUG;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL ABSORPTION; GERIATRIC PATIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0030722238     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Boucher R et al. Tonin, angiotensin II system: a review. Circ Rus 1977; 41: 11-26.
2. Arakawa K, Maruta H. Ability of kalikrein to generate angiotensin II-like substance and a proposed kinin-tensin enzyme system. Nature 1980; 288: 705-706.
3. Tonnesen MG et al. Identification of a human neutrophil angiotensin II-generating protease as cathepsin G. J Clin Invest 1982; 69: 25-30.
4. th edn. MacMillan, New York, 1985: 639.
5. Timmermans PBMWM et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-225.
6. Nishikawa K, Naka T, Chatani F, Yoshimura Y. Candesartan cilexetil: a review of its preclinical pharmacology. J Hum Hypertens 1997; 11 (Suppl 2): S9-S17.
7. Hübner R, Högemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997; 11 (Suppl 2): S19-S25.
8. 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997; 11 (Suppl 2): S27-S28.
9. Belz GG et al. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. J Hum Hypertens 1997; 11 (Suppl 2): S45-S47.
10. Fridman K, Andersson OK, Wysocki M, Friberg P. Effects of an acute dose of 16 mg candesartan cilexetil on systemic and renal haemodynamics in hypertensive patients. J Hum Hypertens 1997; 11 (Suppl 2): S43-S44.
11. Elmfeldt D, George M, Hübner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin Il antagonist, provides dose-dependent antihypertensive effect. J Hum Hypertens 1997; 11 (Suppl 2): S49-S53.
12. Heuer HJ, Schöndorfer G, Högemann AM. 24-hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (Suppl 2): S55-S56.
13. Sever P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (Suppl 2): S69-S73.
14. Grueninger UJ, Strasser T (eds). Educating the hypertensive patient. J Hum Hypertens 1990; 4 (Suppl 1): 1.
15. Belcher G et al. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997; 11 (Suppl 2): S85-S89.
16. O'Kane KPJ, Fridman K, McInnes G. Tolerability and efficacy of candesartan cilexetil 32 mg once daily in hypertensive patients. Am J Hypertens 1997; 10 (4 Pt2): 111A.
17. Trenkwalder P, Lehtovirta M, Dahl K. Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens 1997; 11 (Suppl 2): S81-S83.
18. Andersson OK, Neldam S. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (Suppl 2): S63-S64.
19. Franke H. Antihypertensive effects of candesartan, enalapril and placebo. J Hum Hypertens 1997; 11 (Suppl 2): S61-S62.
20. Zanchetti A, Omboni S, Di Biagio C. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (Suppl 2): S57-S59.
21. Farsang C et al. Antihypertensive effects and tolerability of candesartan cilexetil, amlodipine and their combination. Am J Hypertens 1997; 10 (4 pt 2): 80A.
22. Gradman AH et al. A randomized, placebo-controlled, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-1350.
23. Arakawa K, Ogihara T. Evaluation of the clinical usefulness of TCV-116 (candesartan cilexetil) in patients with essential hypertension. A double-blind, parallel group-comparison study using enalapril maleate as control drug. J Clin Therap Mad 1996; 12: 2613-2661.
24. Simpson FO. Hypertensive disease. In: Speight TM (ed). Avery's Drug Treatment, 3rd edition. Adis International Press: Auckland, 1987, pp 676-731.
25. Philipp T, Letzel H. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate essential hypertension. J Hum Hypertens 1997; 11 (Suppl 2): S67-S68.
26. Plouin P-F. Combination therapy with candesartan cilexetil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide. J Hum Hypertens 1997; 11 (Suppl 2): S65-S66.
27. McInnes GT et al. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 (Suppl 2): S75-S80.
28. MacGregor GA et al. The efficacy of candesartan, an angiotensin II type I receptor antagonist alone or in combination with amlodipine or in combination with amlodipine and hydrochlorothiazide in patients with moderate to severe hypertension. Am J Hypertens 1997; 10 (4 Pt 2): 112A.
29. de Zeeuw D, Remuzzi G, Kirch W. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Hum Hypertens 1997; 11 (Suppl 2): S37-S42.
30. Riddell JG. A study of the food interaction potential of candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997; 11 (Suppl 2): S29-S30.
31. Jonkman JJ et al. Pharmacokinetic drug interaction studies with candesartan cilexetil. J Hum Hypertens 1997; 11 (Suppl 2); S31-S35.